- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr J. Mario Molina Calls for Controlling Growing Medicaid Costs
Specialty drug costs represent a huge concern for Medicaid, which already represents the second largest budget in a state, according to J. Mario Molina, MD, president and chief executive officer of Molina Healthcare.
Specialty drug costs represent a huge concern for Medicaid, which already represents the second largest budget in a state, J. Mario Molina, MD, president and chief executive officer of Molina Healthcare, said in October at the National Conferences on Medicare and Medicaid, and Dual Eligibles Summit held by America’s Health Insurance Plans.
If Medicaid costs are not kept under control, states run the risk of the program’s growing budget cutting into other needed services, he explained.
“The funny thing is the government is willing to set pricing, especially on Medicare, for hospital services and physician services, but they’ve been unwilling to tackle pharmaceuticals,” Dr Molina said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
